SCHEMBL6883044

SCHEMBL6883044

CC1COC(=O)N1c1ccccc1

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NOTUM Q6P988 1/20 0.44
MAOA P21397 1/20 0.43
NAAA Q02083 1/20 0.43
GAA P10253 1/20 0.40
G6PD P11413 1/20 0.40
L3MBTL1 Q9Y468 1/20 0.40
ALOX5 P09917 2/20 0.39
SMN1; SMN2 Q16637 2/20 0.39
MAP4K1 Q92918 2/20 0.37
USP2 O75604 1/20 0.37
ALDH1A1 P00352 1/20 0.37
POLB P06746 1/20 0.37
MAPT P10636 1/20 0.37
HPGD P15428 1/20 0.37
QPCT Q16769 1/20 0.36
MPO P05164 1/20 0.36
GRM2 Q14416 1/20 0.36
IDH1 O75874 1/20 0.35
P2RX7 Q99572 2/20 0.35
KIF11 P52732 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6871051 1.00 NOTUM (0.44) NOTUMMAOANAAAGAAG6PD
SCHEMBL8585033 1.00 NOTUM (0.44) NOTUMMAOANAAAGAAG6PD
SCHEMBL29348773 0.82 MEN1 (0.40) NOTUML3MBTL1ALDH1A1MAPTHPGD
SCHEMBL29348772 0.82 MEN1 (0.40) NOTUML3MBTL1ALDH1A1MAPTHPGD
SCHEMBL29348775 0.82 MEN1 (0.40) NOTUML3MBTL1ALDH1A1MAPTHPGD
SCHEMBL2365942 0.82 USP2 (0.46) NAAAL3MBTL1SMN1; SMN2USP2ALDH1A1
SCHEMBL2365947 0.82 USP2 (0.46) NAAAL3MBTL1SMN1; SMN2USP2ALDH1A1
SCHEMBL22771222 0.80 CYP11B2 (0.47) GAAL3MBTL1ALDH1A1MAPTIDH1
SCHEMBL1937070 0.80 MAP4K1 (0.43) MAP4K1ALDH1A1MAPTGRM2MEN1
SCHEMBL4458253 0.78 PDE3B (0.41) NOTUMMAOANAAAMAP4K1ALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20210379574-A1 MULTI-FUNCTIONALIZED HOLLOW FIBER ORGANOCATALYSTS THE CURATORS OF THE UNIVERSITY OF MISSOURI 2021-12-09 US disclosed
EP-2858983-A1 TNF -ALPHA MODULATING BENZIMIDAZOLES UCB Biopharma SPRL (BE) 2015-04-15 EP disclosed
WO-2013186229-A1 TNF -ALPHA MODULATING BENZIMIDAZOLES UCB PHARMA S.A. (BE) 2013-12-19 WO disclosed
US-20040081682-A1 Transdermal system (tds) that contain inhibitors of phosphodiesterase lV NEUROBIOTEC GMBH (DE) 2004-04-29 US disclosed
EP-1343484-A2 TRANSDERMAL SYSTEMS (TDS) THAT CONTAIN INHIBITORS OF PHOSPHODIESTERASE IV Günther, Clemens (DE) 2003-09-17 EP disclosed
WO-2002049606-A2 TRANSDERMAL SYSTEMS (TDS) THAT CONTAIN INHIBITORS OF PHOSPHODIESTERASE IV GUENTHER CLEMENS (DE) 2002-06-27 WO disclosed
CN-1077103-C Chiral methyl phenyl oxazolidinones SCHERING AG (DE) 2002-01-02 CN disclosed
CN-1077103-C Chiral methyl phenyl oxazolidinones SCHERING AG (DE) 2002-01-02 CN disclosed
CN-1077103-C Chiral methyl phenyl oxazolidinones SCHERING AG (DE) 2002-01-02 CN disclosed
EP-0859766-B1 CHIRAL METHYL PHENYL OXAZOLIDINONES SCHERING AG (DE) 2001-05-16 EP disclosed
US-6025376-A INHIBITORS OF TUMOR NECROSIS FACTOR, TREATING MULTIPLE SCLEROSIS SCHERING AKTIENGESELLSCHAFT (DE) 2000-02-15 US disclosed
CN-1200115-A Chiral methyl phenyl oxazolidinones SCHERING AG (DE) 1998-11-25 CN disclosed
CN-1200115-A Chiral methyl phenyl oxazolidinones SCHERING AG (DE) 1998-11-25 CN disclosed
CN-1200115-A Chiral methyl phenyl oxazolidinones SCHERING AG (DE) 1998-11-25 CN disclosed
EP-0859766-A1 CHIRAL METHYL PHENYL OXAZOLIDINONES SCHERING AKTIENGESELLSCHAFT (DE) 1998-08-26 EP disclosed
EP-0859766-A1 CHIRAL METHYL PHENYL OXAZOLIDINONES SCHERING AKTIENGESELLSCHAFT (DE) 1998-08-26 EP disclosed
WO-1997015561-A1 CHIRAL METHYL PHENYL OXAZOLIDINONES SCHERING AKTIENGESELLSCHAFT (DE) 1997-05-01 WO disclosed
WO-1997015561-A1 CHIRAL METHYL PHENYL OXAZOLIDINONES SCHERING AKTIENGESELLSCHAFT (DE) 1997-05-01 WO disclosed
EP-0632802-A1 NEW ALKYLATING REAGENT, PROCESS FOR PREPARING THE SAME AND ITS USE SCHERING AKTIENGESELLSCHAFT (DE) 1995-01-11 EP disclosed
WO-1993019043-A1 NEW ALKYLATING REAGENT, PROCESS FOR PREPARING THE SAME AND ITS USE SCHERING AKTIENGESELLSCHAFT (DE) 1993-09-30 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040081682-A1 Transdermal system (tds) that contain inhibitors of phosphodiesterase lV PDE12, PDE3B, PDE5A NOTUM 479/4885MAOA 63/4885NAAA 2882/4885
US-20210379574-A1 MULTI-FUNCTIONALIZED HOLLOW FIBER ORGANOCATALYSTS HAAO, DCAF1, HPD NOTUM 487/4885MAOA 1223/4885NAAA 1043/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.